

Paul Thomas Francis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1513747/publications.pdf>

Version: 2024-02-01

235
papers

13,083
citations

20817

60
h-index

27406

106
g-index

246
all docs

246
docs citations

246
times ranked

14256
citing authors

#	ARTICLE	IF	CITATIONS
1	The cholinergic hypothesis of Alzheimer's disease: a review of progress. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 137-147.	1.9	1,714
2	Neurochemical Studies of Early-Onset Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1985, 313, 7-11.	27.0	354
3	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2010, 67, 739.	12.3	353
4	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013, 9, 602-608.	0.8	292
5	Cholinesterase Inhibitors Used in the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2004, 21, 453-478.	2.7	287
6	Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives. <i>Journal of Neurochemistry</i> , 1993, 60, 1589-1604.	3.9	227
7	The Interplay of Neurotransmitters in Alzheimer's Disease. <i>CNS Spectrums</i> , 2005, 10, 6-9.	1.2	217
8	Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1987, 48, 8-15.	3.9	211
9	Evidence of Glutamatergic Denervation and Possible Abnormal Metabolism in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1988, 50, 790-802.	3.9	200
10	Glutamatergic systems in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S15-S21.	2.7	194
11	Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. <i>Neuropsychologia</i> , 2005, 43, 442-449.	1.6	193
12	AddNeuroMed™ The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 36-46.	3.8	193
13	Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. <i>Brain Research</i> , 1987, 401, 231-238.	2.2	187
14	Metals ions and neurodegeneration. <i>BioMetals</i> , 2007, 20, 639-654.	4.1	186
15	Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. <i>Biological Psychiatry</i> , 2002, 51, 407-416.	1.3	173
16	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	7.6	172
17	Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimer's and Dementia</i> , 2017, 13, 84-100.	0.8	167
18	Cholinergic deficits contribute to behavioral disturbance in patients with dementia. <i>Neurology</i> , 2000, 55, 1460-1467.	1.1	164

#	ARTICLE	IF	CITATIONS
19	Downâ€™regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006, 98, 939-950.	3.9	156
20	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. <i>Neurobiology of Aging</i> , 2013, 34, 805-808.	3.1	152
21	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 379, 528-536.	13.7	144
22	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	4.1	144
23	Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. <i>Brain Research</i> , 2003, 974, 82-87.	2.2	141
24	Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. <i>Brain Research</i> , 1987, 414, 365-375.	2.2	138
25	Topographical distribution of neurochemical changes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1988, 84, 125-140.	0.6	137
26	Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 9504-9508.	7.1	137
27	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 104-111.	8.7	134
28	A Double-Blind Placebo-Controlled Randomized Trial of <i>Melissa officinalis</i> Oil and Donepezil for the Treatment of Agitation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 158-164.	1.5	129
29	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2004, 29, 410-416.	5.4	128
30	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, 1149-1158.	0.8	126
31	Neurochemical Features of Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 80-84.	1.5	116
32	Presynaptic Serotonergic Markers in Community-Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication. <i>Journal of Neurochemistry</i> , 1996, 66, 1592-1598.	3.9	116
33	Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. <i>Movement Disorders</i> , 2007, 22, S351-S357.	3.9	116
34	Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. <i>Neuroscience</i> , 1990, 38, 571-577.	2.3	100
35	Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates A β production. <i>Human Molecular Genetics</i> , 2012, 21, 2845-2854.	2.9	100
36	Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. <i>Brain</i> , 2020, 143, 3763-3775.	7.6	100

#	ARTICLE	IF	CITATIONS
37	Identification of Novel β -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	3.3	99
38	Brain amino acid concentrations and Ca ²⁺ -dependent release in intractable depression assessed antemortem. <i>Brain Research</i> , 1989, 494, 315-324.	2.2	94
39	Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 347-355.	3.2	94
40	Neurochemical basis for symptomatic treatment of Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 221-229.	4.1	94
41	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 2836-2844.	3.1	94
42	Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1216-1223.	3.1	85
43	Postmortem serotonergic correlates of cognitive decline in Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 1175-1178.	1.2	84
44	Loss of serotonin 5-HT _{2A} receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. <i>Psychopharmacology</i> , 2005, 179, 673-677.	3.1	83
45	Serotonin 5-HT ₆ Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status. <i>CNS Drugs</i> , 2017, 31, 19-32.	5.9	82
46	Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status. <i>Drugs</i> , 2014, 74, 729-736.	10.9	77
47	Dietary (-)-epicatechin as a potent inhibitor of β -secretase amyloid precursor protein processing. <i>Neurobiology of Aging</i> , 2015, 36, 178-187.	3.1	76
48	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 512-519.	1.9	75
49	The modulation by chlormethiazole of the GABA _A receptor complex in rat brain. <i>British Journal of Pharmacology</i> , 1989, 98, 284-290.	5.4	73
50	Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. <i>Journal of Neurochemistry</i> , 2008, 105, 2466-2476.	3.9	72
51	A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex. <i>Nature Communications</i> , 2021, 12, 3517.	12.8	72
52	Somatostatin content and release measured in cerebral biopsies from demented patients. <i>Journal of the Neurological Sciences</i> , 1987, 78, 1-16.	0.6	70
53	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019, 9, 154.	4.8	69
54	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. <i>Neurochemical Research</i> , 1992, 17, 917-922.	3.3	67

#	ARTICLE	IF	CITATIONS
55	Post-synaptic 5-HT _{1A} and 5-HT _{2A} Receptors Are Increased in Parkinson's Disease Neocortex. <i>Annals of the New York Academy of Sciences</i> , 1998, 861, 288-289.	3.8	67
56	Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 711-719.	1.3	67
57	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. <i>Movement Disorders</i> , 2016, 31, 352-359.	3.9	66
58	NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT _{1A} antagonist. <i>British Journal of Pharmacology</i> , 1995, 115, 1169-1174.	5.4	65
59	Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 929-936.	1.7	65
60	Î²1-42 modulation of Akt phosphorylation via Î±7 nAChR and NMDA receptors. <i>Neurobiology of Aging</i> , 2008, 29, 992-1001.	3.1	65
61	d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. <i>Brain Research</i> , 1991, 565, 345-348.	2.2	63
62	The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. <i>Journal of Neural Transmission</i> , 1998, 105, 839-853.	2.8	63
63	Cholinergic imbalance in the multiple sclerosis hippocampus. <i>Acta Neuropathologica</i> , 2011, 122, 313-322.	7.7	63
64	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2021, 26, 5766-5788.	7.9	63
65	Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. <i>Psychopharmacology</i> , 2008, 196, 603-610.	3.1	62
66	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. <i>Neurochemistry International</i> , 2010, 57, 985-989.	3.8	59
67	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1110-1117.	3.1	56
68	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	2.7	54
69	Age-related alteration in excitatory amino acid neurotransmission in rat brain. <i>Neurobiology of Aging</i> , 1990, 11, 155-158.	3.1	50
70	Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. <i>Journal of Neural Transmission</i> , 2008, 115, 1165-1172.	2.8	49
71	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 232-241.	1.7	49
72	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 330-338.	1.5	48

#	ARTICLE	IF	CITATIONS
73	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019, 29, 63-74.	4.1	48
74	Glutamatergic Approaches to the Treatment of Cognitive and Behavioural Symptoms of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 241-243.	1.4	47
75	Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. <i>Current Molecular Pharmacology</i> , 2009, 2, 77-82.	1.5	47
76	Treatment strategies for Alzheimer's disease. <i>Lancet, The</i> , 1992, 339, 132-133.	13.7	46
77	Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1285-1297.	3.0	45
78	Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. <i>Neurobiology of Aging</i> , 1984, 5, 183-186.	3.1	44
79	Pharmacological profile of an essential oil derived from <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 377-384.	2.4	44
80	Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1995, 65, 2165-2169.	3.9	42
81	A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. <i>Molecular Psychiatry</i> , 2020, 25, 629-639.	7.9	42
82	Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with A β burden. <i>Neurochemistry International</i> , 2014, 64, 29-36.	3.8	41
83	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 352-365.	3.2	41
84	Animal and drug modelling for Alzheimer synaptic pathology. <i>Progress in Neurobiology</i> , 1992, 39, 517-545.	5.7	40
85	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 1121-1133.	0.8	40
86	Involvement of an Altered 5-HT ₆ Receptor Function in Behavioral Symptoms of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 43-50.	2.6	39
87	Differential involvement of hippocampal serotonin 1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. <i>Psychopharmacology</i> , 2011, 213, 431-439.	3.1	39
88	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1351-1365.	2.8	39
89	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2008, 60, 1515-1522.	2.4	39
90	Characterisation of the Glycine Modulatory Site of the N-Methyl-d-Aspartate Receptor-Ionophore Complex in Human Brain. <i>Journal of Neurochemistry</i> , 1991, 56, 299-310.	3.9	38

#	ARTICLE	IF	CITATIONS
91	A serotonergic basis for hyperphagic eating changes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2010, 288, 151-155.	0.6	38
92	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 659-668.	2.6	38
93	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 141-148.	1.2	38
94	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	1.2	38
95	Choline Acetyltransferase Activity in Vascular Dementia and Stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 233-238.	1.5	36
96	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1515-1522.	2.4	36
97	Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer's Disease. <i>Scientific Reports</i> , 2017, 7, 42874.	3.3	36
98	Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones. <i>Brain Research</i> , 1993, 632, 86-94.	2.2	35
99	Aggressive Behavior and Neuroleptic Medication Are Associated With Increased Number of Alpha1-Adrenoceptors in Patients With Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 435-437.	1.2	35
100	Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2798-2806.	3.1	35
101	Whole-exome sequencing of the BDR cohort: evidence to support the role of the <i>PILRA</i> gene in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 506-521.	3.2	35
102	Are post-mortem biochemical studies of human brain worthwhile?. <i>Biochemical Society Transactions</i> , 1988, 16, 472-475.	3.4	34
103	Neurotransmission—the link integrating Alzheimer research?. <i>Trends in Neurosciences</i> , 1994, 17, 149-150.	8.6	34
104	A novel protein, amyloid precursor-like protein 2, is present in human brain, cerebrospinal fluid and conditioned media. <i>Biochemical Journal</i> , 1995, 310, 95-99.	3.7	34
105	Vesicular glutamate transporter and cognition in stroke. <i>Neurology</i> , 2010, 75, 1803-1809.	1.1	34
106	Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11± protein up-regulation in Alzheimer's disease. <i>Neuroscience</i> , 2006, 138, 511-522.	2.3	32
107	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. <i>Brain</i> , 2009, 132, 1858-1865.	7.6	32
108	Pro-oxidant diet enhances β^2/β^3 secretase-mediated APP processing in APP/PS1 transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 960-968.	3.1	32

#	ARTICLE	IF	CITATIONS
109	Amyloid β concentrations in older people with Down syndrome and dementia. <i>Neuroscience Letters</i> , 2009, 451, 162-164.	2.1	31
110	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1487-1497.	13.7	31
111	Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from <i>Adenia volkensis</i> . <i>Journal of Neuroscience Methods</i> , 1991, 40, 17-29.	2.5	30
112	Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 278-286.	1.5	30
113	Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. <i>Journal of Proteomics</i> , 2014, 99, 54-67.	2.4	30
114	Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. <i>Neuroscience Letters</i> , 2013, 557, 177-180.	2.1	29
115	Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. <i>Journal of Neurology</i> , 2009, 256, 280-285.	3.6	28
116	Clusterin Associates Specifically with β 40 in Alzheimer's Disease Brain Tissue. <i>Brain Pathology</i> , 2013, 23, 623-632.	4.1	28
117	Neurotransmitters and Second Messengers in Aging and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 19-26.	3.8	27
118	[³ H]GR113808 binding to serotonin 5-HT ₄ receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. <i>Journal of Neural Transmission</i> , 2003, 110, 779-788.	2.8	26
119	Selective effects of the APOE ϵ 4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2006, 22, 555-561.	4.4	26
120	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β -amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	2.6	26
121	Preliminary Neurochemical Findings in Non-Alzheimer Dementia due to Lobar Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 1993, 4, 172-177.	1.5	25
122	Increased Transforming Growth Factor β 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A β 42 Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	2.6	25
123	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. <i>Molecular Brain</i> , 2017, 10, 36.	2.6	25
124	Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties. <i>Neuropharmacology</i> , 2012, 62, 2208-2218.	4.1	24
125	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 101-110.	2.6	24
126	Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1635-1644.	2.6	24

#	ARTICLE	IF	CITATIONS
127	â€œTraditionalâ€™ pharmacotherapy may succeed in Alzheimer's disease. Trends in Neurosciences, 1992, 15, 84-85.	8.6	23
128	Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 80-84.	1.9	22
129	Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes. European Journal of Pharmacology, 1990, 189, 195-200.	2.6	21
130	Isoformâ€™specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. Brain Pathology, 2021, 31, 253-266.	4.1	21
131	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 5177-5183.	4.0	21
132	The dementia of Alzheimer's disease: an update.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 242-243.	1.9	20
133	NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones. Brain Research, 1992, 596, 223-230.	2.2	20
134	Î±-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. International Psychogeriatrics, 2010, 22, 321-327.	1.0	20
135	An isoformâ€™specific role of FynT tyrosine kinase in Alzheimer's disease. Journal of Neurochemistry, 2016, 136, 637-650.	3.9	20
136	Expression of Amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deafferentation lesions. Brain Research, 2001, 907, 222-232.	2.2	19
137	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. NeuroReport, 2003, 14, 1297-1300.	1.2	19
138	Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes. Dementia and Geriatric Cognitive Disorders, 2011, 31, 247-253.	1.5	19
139	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 793-801.	2.6	19
140	Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimerâ€™s disease patients with psychosis. Psychopharmacology, 2008, 198, 251-259.	3.1	17
141	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimerâ€™s disease. Brain, 2020, 143, 3842-3849.	7.6	17
142	Effect of Psychotropic Drugs on Excitatory Amino Acids in Patients Undergoing Psychosurgery for Depression. British Journal of Psychiatry, 1992, 160, 638-642.	2.8	16
143	Pyramidal Neurone Modulation: A Therapeutic Target for Alzheimer's Disease. Experimental Neurology, 1996, 5, 461-465.	1.7	16
144	Cholinergic and glutamatergic drugs in Alzheimerâ€™s disease therapy. Expert Review of Neurotherapeutics, 2005, 5, 671-682.	2.8	16

#	ARTICLE	IF	CITATIONS
145	Targeting Cell Death in Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S3-S7.	1.3	16
146	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer's disease are not present in diabetic Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 11386.	3.3	16
147	Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease. <i>Journal of Neurodegenerative Diseases</i> , 2017, 2017, 1-13.	1.1	15
148	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	1.6	15
149	Relevance of reduced concentrations of somatostatin in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 1985, 13, 170-171.	3.4	14
150	Postmortem brains reveal similar but not identical amyloid precursor protein-like immunoreactivity in Alzheimer compared with other dementias. <i>Brain Research</i> , 1994, 644, 347-351.	2.2	14
151	5-HT1B and other related serotonergic proteins are altered in APP ^{swe} mutation. <i>Neuroscience Letters</i> , 2015, 594, 137-143.	2.1	14
152	Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients. <i>Psychopharmacology</i> , 2016, 233, 591-598.	3.1	14
153	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 373-386.	2.6	14
154	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 283-293.	1.5	14
155	Tacrine, a Drug with Therapeutic Potential for Dementia: Post-Mortem Biochemical Evidence. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 504-510.	0.5	13
156	Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease. <i>British Journal of Psychiatry</i> , 1991, 158, 558-562.	2.8	13
157	The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in A β ²⁵⁻³⁵ (1-42)-injected male Wistar rats. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1022-1030.	2.4	12
158	Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimer's disease. <i>BMC Research Notes</i> , 2018, 11, 646.	1.4	12
159	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1-9.	2.7	12
160	Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions. <i>Journal of Neural Transmission</i> , 2001, 108, 809-826.	2.8	11
161	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1146-1152.	2.7	11
162	Changes in Hypothalamic Monoamine Concentrations Accompany the Progesterone-Induced Release of Luteinizing Hormone in the Domestic Hen. <i>Neuroendocrinology</i> , 1982, 35, 359-362.	2.5	10

#	ARTICLE	IF	CITATIONS
163	The effect of testosterone on the release of endogenous catecholamines from the hypothalamus of the cockerel in vitro. <i>Psychoneuroendocrinology</i> , 1984, 9, 69-76.	2.7	10
164	Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. <i>Journal of Neural Transmission</i> , 2012, 119, 1467-1476.	2.8	10
165	Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia. <i>Neurochemistry International</i> , 2019, 129, 104502.	3.8	10
166	Cerebral amyloid angiopathy distribution in older people: A cautionary note. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12145.	3.7	10
167	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 349-361.	2.6	9
168	Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. <i>Brain Communications</i> , 2020, 2, fcaa167.	3.3	9
169	Pyramidal neuron loss and "glycine-site therapy": A need for an animal model and study in late-life depression. <i>Neurobiology of Aging</i> , 1989, 10, 616-618.	3.1	8
170	Changes in Cortical Nicotinic Acetylcholine Receptor Numbers Following Unilateral Destruction of Pyramidal Neurones by Intrastriatal Volkensin Injection. <i>Experimental Neurology</i> , 1995, 4, 415-424.	1.7	8
171	Changes in hippocampal SNAP-25 expression following afferent lesions. <i>Brain Research</i> , 2004, 997, 133-135.	2.2	8
172	Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet. <i>Neurochemistry International</i> , 2010, 57, 504-511.	3.8	8
173	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	3.8	8
174	Protection from dementia. <i>Science</i> , 1992, 258, 1422-1423.	12.6	7
175	Soluble A β -amyloid precursor protein and pyramidal neuron loss. <i>Lancet, The</i> , 1993, 341, 431.	13.7	7
176	Genetic variation in the 5-HT _{2A} receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease. <i>Neuroscience Letters</i> , 2007, 420, 58-60.	2.1	7
177	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid A β ₄₀ and tau in patients with intractable unipolar depression. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1283-1291.	2.7	7
178	Ticking boxes or meaningful partnership "The experience of lay representation, participant and study partner involvement in Brains for Dementia Research. <i>Dementia</i> , 2018, 17, 1023-1034.	2.0	7
179	The stability of 5-hydroxyindoleacetic acid and noradrenaline in normal and Alzheimer post mortem brain. <i>Biochemical Society Transactions</i> , 1986, 14, 608-609.	3.4	6
180	Lack of Change in Neurochemical Markers During the Postepileptic Phase of Intrahippocampal Tetanus Toxin Syndrome in Rats. <i>Epilepsia</i> , 1990, 31, 697-701.	5.1	6

#	ARTICLE	IF	CITATIONS
181	Selective Loss of Cholinergic Receptors Following Unilateral Intracortical Injection of Volkensin. <i>Experimental Neurology</i> , 1997, 147, 183-191.	4.1	6
182	Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 1104-1106.	2.7	6
183	Genotyping of the Alzheimer's Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 355-362.	2.6	6
184	Brains for Dementia Research: The Importance of Cohorts in Brain Banking. <i>Neuroscience Bulletin</i> , 2019, 35, 289-294.	2.9	6
185	Treatment of Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 328-328.	1.9	5
186	Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 112-112.	5.3	5
187	Factors affecting the β -amyloid precursor in PC12 cells. <i>Biochemical Society Transactions</i> , 1993, 21, 239S-239S.	3.4	5
188	A pilot study of potential brain donor satisfaction and attitudes towards telephone assessment. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1247-1256.	2.7	5
189	Effect of Li+ therapy and site of origin on cerebrospinal fluid β -amyloid precursor protein derivatives. <i>Biochemical Society Transactions</i> , 1993, 21, 242S-242S.	3.4	4
190	Brain Membrane Serine Protease Activity in Human Cortex Compared with Rat: Implication for Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1994, 5, 62-68.	1.5	4
191	The 5-HT 1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. <i>Psychopharmacology</i> , 1996, 127, 245-254.	3.1	4
192	Neuronal Degeneration by Suicide Transport Following Injection of Volkensin into Rat Cerebral Cortex. <i>Experimental Neurology</i> , 1997, 147, 192-203.	4.1	4
193	Glutamate toxicity in rat cultured neurones: effects on amyloid precursor-like protein 2. <i>Neuroscience Letters</i> , 1999, 276, 107-110.	2.1	4
194	Differential Alterations of Neocortical GluN Receptor Subunits in Patients with Mixed Subcortical Ischemic Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 431-437.	2.6	4
195	Brain aging research at the close of the 20th century: from bench to bedside. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 167-180.	3.7	4
196	Dynamin protein in stroke and vascular dementia. <i>Neuroscience Letters</i> , 2014, 563, 118-122.	2.1	3
197	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	2.8	3
198	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	2.8	3

#	ARTICLE	IF	CITATIONS
199	Assessment of respiratory morbidity among bus drivers and conductors of the state road transport corporation, Kochi, Kerala. Journal of Family Medicine and Primary Care, 2019, 8, 3887.	0.9	3
200	Relationship between β -amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. Biochemical Society Transactions, 1993, 21, 238S-238S.	3.4	2
201	New Approaches to Imaging Based on Effects of Neurotoxins. Dementia and Geriatric Cognitive Disorders, 1997, 8, 117-122.	1.5	2
202	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. NeuroReport, 2003, 14, 1297-1300.	1.2	2
203	Surveillance of acute flaccid paralysis in India. Lancet, The, 2007, 369, 1322-1323.	13.7	2
204	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. International Psychogeriatrics, 2013, 25, 687-689.	1.0	2
205	Utilization of Anganwadi Services in a Rural Population of Kerala. Indian Pediatrics, 2017, 54, 65-66.	0.4	2
206	Excitatory amino acid neurotransmitters, somatostatin and degenerate cortical neurons in Alzheimer's disease. Biochemical Society Transactions, 1986, 14, 911-912.	3.4	1
207	A cortical pyramidal neurone neurotransmitter receptor that may affect β -amyloid precursor protein. Biochemical Society Transactions, 1993, 21, 240S-240S.	3.4	1
208	SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 600S-600S.	3.4	1
209	NON-SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 601S-601S.	3.4	1
210	Neurochemistry of severe dementia. Reviews in Clinical Gerontology, 2005, 15, 105-123.	0.5	1
211	Protective efficacy of a monovalent oral type 1 poliovirus vaccine. Lancet, The, 2007, 370, 129.	13.7	1
212	Spreading Pathologies Precede Cognitive Decline in Alzheimer's Disease. Biological Psychiatry, 2015, 77, 678-679.	1.3	1
213	Factors affecting withdrawal and donation attrition in the brains for dementia research cohort. International Journal of Geriatric Psychiatry, 2018, 33, 1709-1716.	2.7	1
214	Current Neurotransmitter Strategies in AD Drug Development. Advances in Behavioral Biology, 1998, , 851-859.	0.2	1
215	Impact of Swachh Bharat Abhiyan on residents of Cochin corporation. Indian Journal of Community Medicine, 2019, 44, 19.	0.4	1
216	Protease α -Clipsin extract activity reflects demographic characteristics of human brain. Neuroscience Letters, 1992, 143, 43-47.	2.1	0

#	ARTICLE	IF	CITATIONS
217	Protease α -Clipsin activity and β -amyloid precursor protein degradation by Alzheimer brain. <i>Biochemical Society Transactions</i> , 1993, 21, 241S-241S.	3.4	0
218	Neurotransmitter Changes in Alzheimer's Disease: Relationships to Symptoms and Neuropathology. , 0, , 229-232.		0
219	Synaptic protein expression is regulated by a pro-oxidant diet in APPxPS1 mice. <i>Journal of Neural Transmission</i> , 2012, 119, 493-496.	2.8	0
220	Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S7794.	0.4	0
221	Correspondence. <i>Indian Pediatrics</i> , 2017, 54, 63-66.	0.4	0
222	[P1 α 235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBUNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P333.	0.8	0
223	Language Barrier in Anganwadis in Eranakulam, Kerala. <i>Indian Pediatrics</i> , 2021, 58, 793-794.	0.4	0
224	Dopaminergic and Glutamatergic Systems in Alzheimer's Disease. , 2005, , 569-581.		0
225	Cholinergic and Serotonergic Systems in Severe Dementia. , 0, , 21-31.		0
226	The Rationale for Glutamatergic Therapy in Alzheimer's Disease. , 2007, , 105-112.		0
227	Glutamatergic Hypoactivity in Alzheimer's Disease: Investigative and Therapeutic Perspectives. , 1994, , 354-358.		0
228	Neuronal pathology in relation to molecular biology and treatment of Alzheimer's disease. , 1994, 4, 25-54.		0
229	Glutamatergic Function in Alzheimer's Disease. , 1997, , 153-159.		0
230	The Rationale for Development of Cholinergic Therapies in ad. <i>Advances in Behavioral Biology</i> , 1998, , 445-450.	0.2	0
231	Transgenerational preventive practices of diabetes mellitus type II patients attending a tertiary care hospital in Cochin, India. <i>Indian Journal of Community Medicine</i> , 2019, 44, 7.	0.4	0
232	Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimer's Disease. , 2008, , 403-409.		0
233	Vaccine Preventable Diseases (VPD) and Public Health. <i>Indian Pediatrics</i> , 2019, 56, 1064.	0.4	0
234	Language Barrier in Anganwadis in Eranakulam, Kerala. <i>Indian Pediatrics</i> , 2021, 58, 793-794.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 267-267.	2.4	0